With over thirty years of experience in the field of business, Robert Mackie has built an extensive portfolio of successful ventures. As a result of his knowledge, Robert has been well sought after by many companies for his expertise in leadership as well as building, transforming, and transcending businesses. His experience includes, but is not limited to, business-to-business relations, corporate takeovers and restructurings, sales and marketing strategy, oversight of finances, as well as import/export and trading. Beginning his career as an entrepreneur, one of Robert’s esteemed business endeavors includes successfully co-founding and owning one of the largest mobile communications companies in Western Canada. In addition, throughout the past twenty years, Robert has formed an exceptional international portfolio in the development and management of Commercial Real Estate. Born and raised in British Columbia, Robert has always placed an importance on being involved in the community. He has been actively involved in a number of charitable organizations as well as headed several fundraising events for community sports, youth educational programs, and countless other organizations.
Livleen Veslemes has over 15 years of financial management experience in private and public companies across several different industries including biotechnology. Livleen served as Chief Financial Officer of a Vancouver based publicly traded medical diagnostic manufacturer with FDA cleared products that transitioned from the R&D phase into full commercialization through worldwide partnerships with 3M Healthcare, Roche Diagnostics and other international distributors. She also served as the Director of Finance at a subsidiary of Bell Canada and a leading North American provider of satellite communication solutions. She successfully led the financial integration of three North American acquisitions, managed the accounting and finance functions through a period of exponential revenue growth, and was responsible for consolidated financial statements for 2 US subsidiaries and 5 Canadian offices during her tenure there. Immediately prior to joining bioLytical Laboratories in October 2014, Livleen was an executive team member at Luvo Inc. reporting directly to the CEO, hired at startup to develop and lead accounting, finance, supply chain, legal, HR, administration and information systems. She facilitated the implementation of a strategic plan that resulted in the launch of 34 USDA approved products with 5,500 retailers in the US including Whole Foods, Safeway, Target and Costco. Livleen earned her designation as a Certified Management Accountant (CMA) in 2001.
Stan Miele joined bioLytical Laboratories in March of 2016 as the Chief Commercial Officer. He is an accomplished global executive with over 25 years of sales and marketing experience. He has had success in sales, marketing and P&L leadership in the pharmaceuticals, medical device, diagnostics and biotech industries. He has a proven record of accelerating sales and enhancing profitability, building commercial organizations, negotiating global alliances and leading product launches. His previous role was with Sucampo Pharmaceuticals Inc. where he served as Chief Commercial Officer. He was also the former President of Sucampo Pharma Americas, LLC, since 2009 where he played an important role in in the company achieving profitability in 2013. Mr. Miele joined Sucampo in 2006 as National Director of Sales and was subsequently promoted to Senior Vice President of Sales and Marketing in 2008.
Prior to joining Sucampo, Mr. Miele was the i-STAT Executive Sales Manager for Abbott Diagnostics, a division of global healthcare company Abbott Laboratories, from 2005 to 2006. From 1998 to 2005, he held a series of positions at Millennium Pharmaceuticals and at COR Therapeutics, including National Sales Director, Cardiology. He was also instrumental in the development and launch of an office based cardiovascular sales team during his tenure at Millennium.
Mr. Miele began his career as a sales representative both at the Hospital Products Division of Abbott Laboratories, and at Syntex Labs. He also has served in the military as an officer in the US Army and Army National Guard.
Mr. Miele earned a bachelor’s degree in management communications from the University of Dayton.
After graduation from the University of Windsor with a degree in Microbiology, Rick Galli began his extensive career in research and diagnostic laboratory sciences with the Ontario Ministry of Health and Long Term Care Public Health Laboratory in 1973. Since then he has worked in senior positions in public and hospital laboratory settings as well as the private sector. He was directly involved with leadership of laboratory diagnosis and monitoring of HIV infection from 1987 to 2005, and served on numerous HIV advisory boards and associations, most recently as President of the Canadian Association of HIV Clinical Laboratory Specialists. Before moving to Vancouver and joining the BC Centre for Excellence in HIV/AIDS in 1999, Rick initiated the first and only provincial peer-reviewed HIV/AIDS grants and awards program of its kind for Ontario-based researchers, through the Ontario HIV Treatment Network in Toronto. From 1999 to 2005, Rick helped establish and managed the first accredited HIV molecular laboratory monitoring program in Canada at the BC Center for Excellence in HIV/AIDS. Since joining bioLytical Laboratories in February 2005, Rick has been instrumental in directing the regulatory compliance elements for bioLytical and INSTI that resulted in Health Canada approval, CE Marking for European Union member countries, WHO prequalification and US FDA approval and CLIA waiver. Mr. Galli is responsible for bioLytical Laboratories' regulatory, scientific and clinical affairs.
Dr. Zaharik is an accomplished Research and Development professional with over 15 years of experience in the design and management of novel research paths and research teams in both academic and industrial settings. She has experience managing cross-departmental teams through all stages of product development from feasibility through to commercialization, with a focus on excellent product quality, ease of manufacturability and cost-effectiveness. Dr. Zaharik’s strengths include building strong research teams, cross-functional project management, and a passion for translating scientific advances into diagnostics that will improve the quality and access to care for patients worldwide.
Dr. Zaharik has a Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, and completed her post-doctoral training at the BC CDC. Michelle spent nine years at Response Biomedical Corp. in various positions including Director of Product Development where she was responsible for the design and development of rapid diagnostic tests for cardiovascular and thromboembolic diseases, and Director of Scientific and Regulatory Affairs where she designed and managed clinical studies and regulatory submissions for new RAMP® products.
Angela Tapu is a quality assurance and regulatory affairs professional with more than 20 years industry experience. Angela holds a B.Sc. in Chemical Engineering from the Polytechnic University of Bucharest, a Diploma in Business Administration from the British Columbia Institute of Technology (BCIT) and a Certificate in Biomedical Regulatory Affairs from the University of Washington. Prior to joining BioLytical Laboratories, Angela managed the quality assurance operations at Kardium Inc. which is developing Globe®, a mapping and ablation system for the diagnosis and treatment of atrial fibrillation. Previously, she worked at Response Biomedical Inc. in compliance and quality management for the manufacturing and marketing of rapid diagnostic tests for cardiovascular and infectious disease, biodefence and environmental on RAMP®.
Alka Patel joined BioLytical Laboratories in March 2015. Alka has a B.Sc. in Biochemistry from the University of Auckland, New Zealand and a Diploma in Biotechnology from the British Columbia Institute of Technology (BCIT), Canada. She has over 18 years of experience in the medical device industry covering Product Development, Manufacturing, Supply chain and Logistics. Prior to joining BioLytical Laboratories, Alka worked at Kardium Inc., which is developing Globe ®, a mapping and ablation system for the diagnosis and treatment of atrial fibrillation, where she successfully implemented the ERP system. Before Kardium, she worked at Response Biomedical Inc. for 13 years in various roles managing Manufacturing, Purchasing and Logistics operations of rapid diagnostic tests for cardiovascular and infectious disease, biodefence and environmental on RAMP® technology. Alka also spent 4 years with ID Biomedical, developing diagnostic test for MRSA and VRE detection.
Jenn Hepburn is a CPA, CMA who brings bioLyical Laboratories 10 years of industry experience with public companies in financial reporting, strategic planning, operations, project management and system implementation. Her progressive experience as an accountant includes delivering best practices for reporting under IFRS in addition to regulatory compliance. Prior to joining bioLytical Laboratories, Jenn served as the Controller for three diverse silver and gold exploration and mining companies with projects in Canada, the United States and Mexico. Within these public companies, she managed the accounting and finance functions and was responsible for the consolidated financial statements of each company including their respective Mexican and US subsidiaries. During her tenure there, Jenn provided insight and guidance on complex accounting implications arising from acquisitions and financings, and most recently, successfully led the threefold implementations of an ERP, a BI and a CPM system. Jenn has full cycle accounting experience and previously, validated and implemented the necessary internal controls required for Sarbanes Oxley compliance at a publicly traded medical device manufacturer. Jenn holds a Bachelors of Business Administration in Accounting and Marketing from Simon Fraser University and earned her designation as a CMA in 2012.